Nevirapine

證據等級: L5

預測適應症: 3 個

NEVIRAPINE: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) whose known pharmacology targets HIV-1 infection. The TxGNN model predicts a top-ranked association with Simian Immunodeficiency Virus (SIV) Infection, but the supporting evidence — 0 clinical trials and 17 literature items, none confirming activity against SIV in vivo — indicates this is likely a knowledge-graph artifact (HIV-1/SIV taxonomic proximity) rather than a real pharmacological signal, and SIV is not a human disease.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (per drug mechanism description in evidence pack; no formal license/indication record provided)
Predicted New Indication	Simian Immunodeficiency Virus Infection
TxGNN Prediction Score	99.85%
Evidence Level	L4
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, no formal mechanism-of-action record is available in this evidence pack (original_moa is unrecorded). Based on the mechanistic notes accompanying the prediction, nevirapine is an NNRTI whose binding pocket is highly specific to HIV-1 reverse transcriptase.

The predicted indication, SIV infection, belongs to a different lentivirus lineage. Multiple items in the literature set (e.g., PMID 7541200, PMID 15564466) show that wild-type SIV reverse transcriptase is not meaningfully inhibited by NNRTIs such as nevirapine — sensitivity has only been demonstrated in engineered SHIV chimeras where the SIV RT gene is replaced by HIV-1 RT. This suggests the TxGNN score reflects graph-level proximity between HIV-1 and SIV (both lentiviruses, both studied via shared reverse-transcriptase literature) rather than a genuine drug-disease pharmacological relationship.

Additionally, SIV infection is a disease of non-human primates used as an animal model for HIV research, not a human clinical indication. Even if the mechanistic signal were stronger, this candidate would not represent an actionable human repurposing opportunity without further translational justification.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11020686	2000	Review (human HIV PEP context, not SIV-specific)	Annals of Emergency Medicine	Discusses antiretroviral postexposure prophylaxis; SIV data cited only as indirect animal-model support for human HIV PEP
15564466	2004	In vitro characterization	Journal of Virology	SIV/HIV chimera expressing HIV-1 RT was built specifically because native SIV RT is not effectively inhibited by NNRTIs
19195672	2009	Animal model (SHIV transmission)	Virology	Characterizes an RT-SHIV chimera (HIV-1 RT inserted into SIV backbone) for vaginal transmission studies in macaques
7541200	1995	In vitro resistance profiling	Biochemical and Biophysical Research Communications	Native SIV is inhibited only by nucleoside RT inhibitors, not NNRTIs; an RT-SHIV chimera was required for NNRTI sensitivity
11375059	2001	In vivo animal model	AIDS Research and Human Retroviruses	Uses RT-SHIV (SIV with HIV-1 RT substitution) as a resistance-development model; underscores that native SIV is not an NNRTI target
27748043	2017	In vitro antiviral screening	Chemical Biology & Drug Design	A novel small molecule (3G11) inhibited HIV-1 but explicitly did not block SIVmac or other non-HIV-1 retroviruses
15040537	2004	In vitro susceptibility panel	Antiviral Therapy	Evaluated 16 approved anti-HIV-1 drugs (including NNRTIs) against HIV-2, SIV, and SHIV strains to inform PEP/treatment guidance
12234864	2002	In vitro combination study	Antimicrobial Agents and Chemotherapy	Nevirapine combined with an HIV-1 integrase inhibitor was tested against SIV(MAC251); combination effect was subsynergistic
16859727	2006	In vitro virucide study	Virology	Nevirapine and other NNRTIs/NRTIs were tested for inactivation of HIV-1 and SIV virions via endogenous reverse transcription inhibition
1283296	1992	In vitro antiviral screening	Antimicrobial Agents and Chemotherapy	A different nucleoside analog (FTC) — not nevirapine — showed activity against HIV-1/2, SIV, and FIV; included for cross-species susceptibility context

US Market Information

Nevirapine is not currently marketed in this jurisdiction (market status: 未上市); no NDA or license records are available in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The literature consistently indicates that native SIV reverse transcriptase is resistant to NNRTIs including nevirapine — sensitivity has only been shown in artificially engineered SHIV chimeras carrying HIV-1 RT. Combined with the absence of any clinical trial data and SIV not being a human disease, the evidence does not support advancing this candidate; the TxGNN score is more likely explained by lentivirus taxonomic proximity in the knowledge graph than by genuine drug-disease efficacy.

For reference, the two lower-ranked candidates in this evidence pack (feline immunodeficiency virus-related disease, rank 2; a rare pediatric neurodevelopmental disorder, rank 3) were also scored Hold — the former lacks in vivo efficacy data and is a veterinary indication, and the latter has no supporting literature or plausible mechanistic link at all.

To proceed, the following is needed:

TFDA label warnings/contraindications (currently a Blocking data gap — required before any S1 safety screening)
Confirmed original mechanism-of-action record from DrugBank (currently a High-severity data gap)
A specific molecular/pathway hypothesis connecting nevirapine’s NNRTI activity to a genuine human disease target, rather than relying on SIV/FIV animal-model literature
If pursuing further, in vivo efficacy data against wild-type (non-chimeric) target pathogens
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.